TipRanks on MSN

C4 Therapeutics Reports Promising Phase 1 Trial Results

The latest announcement is out from C4 Therapeutics ( (CCCC) ).
Nasdaq

C4 Therapeutics Reports Promising Cemsidomide Data in Multiple Myeloma and Announces Strategic Development Priorities

C4 Therapeutics, Inc. (C4T) announced promising results from the latest data on its investigational drug cemsidomide for treating multiple myeloma, showing a 50% overall response rate (ORR) at the ...

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed ...

The Phase 1b trial will evaluate the safety and tolerability of cemsidomide, an IKZF1/3 degrader, and dexamethasone in combination with elranatamab as a second line or later therapy for patients with ...
TipRanks on MSN

C4 Therapeutics Partners with Pfizer for Clinical Trial

The latest announcement is out from C4 Therapeutics ( (CCCC) ).